Skip to main content

Table 2 Comparison of clinical responses pre- and post-prostatic artery embolization

From: Safety and efficacy of prostatic artery embolization in patients with hematuria due to benign prostate hyperplasia

P. variable

Q. baseline

R. 3 months

S. 6 months

T. overall

MRI prostate volume, mL

68.2 ± 8.39

52.9 ± 7.91

39.4 ± 5.78

 < 0.0001

HB, g/L

117 ± 4.61

143 ± 2.86

144 ± 2.91

 < 0.0001

IPSS

25.3 ± 3.93

15.7 ± 2.37

7.23 ± 0.96

 < 0.0001

Qmax, mL/s

7.09 ± 1.75

8.58 ± 2.11

15.3 ± 2.34

 < 0.0001

PSA, ng/mL

6.95 ± 1.40

6.68 ± 0.78

6.24 ± 1.24

 < 0.0001

QoL score

4.43 ± 0.25

2.34 ± 0.38

1.57 ± 0.59

 < 0.0001

IIFFS

4.34 ± 1.41

14.6 ± 1.02

19.4 ± 1.16

 < 0.0001

  1. MRI, magnetic resonance imaging; HB, hemoglobin; IPSS, International Prostatic Symptoms Score; Qmax, maximum urinary flow rate; PSA, prostate-specific antigen; QoL, quality of life; and IIEFS, International Index of Erectile Function Score